Edesa Biotech is trading 13.57% down at $4.97 after pricing an underwritten public offering at $5.50 per share-and-warrant combination, below the previous close, creating dilution pressure.
- Announced August 19, 2026, the offering includes common shares or pre-funded warrants with accompanying warrants.
- Gross proceeds are expected at approximately $25.0 million for working capital, research, development, manufacturing, and other corporate purposes.
- Expected to close August 21, 2026, subject to customary conditions; Guggenheim Securities is sole book-running manager.